In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis
- 1 December 1993
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 37 (12) , 2584-2587
- https://doi.org/10.1128/aac.37.12.2584
Abstract
We compared MICs and MBCs of various free- and liposome-incorporated antimicrobial agents against several patient isolates of Mycobacterium avium-M. intracellulare complex and certain American Type Culture Collection strains of M. avium, M. intracellulare, and Mycobacterium tuberculosis. Seven of 19 agents were selected for incorporation into liposomes. The MICs of these agents for 50 and 90% of isolates tested (MIC50s and MIC90s, respectively) ranged from 0.5 to 62 micrograms/ml. Members of the M. avium-M. intracellulare complex were resistant to killing by most of the other agents tested in the free form. However, clofazimine, resorcinomycin A, and PD 117558 showed complete killing of bacteria at concentrations ranging from 8 to 31 micrograms/ml, represented as MBC90s. Among the liposome-incorporated agents, clofazimine and resorcinomycin A had the highest killing effects (MBC90s, 8 and 16 micrograms/ml, respectively). Furthermore, both free and liposome-incorporated clofazimine had equivalent growth-inhibitory and killing effects on all American Type Culture Collection strains of M. avium, M. intracellulare, and M. tuberculosis tested. These results show that the antibacterial activities of certain drugs, particularly those of clofazimine and resorcinomycin, were maintained after the drugs were incorporated into liposomes.Keywords
This publication has 30 references indexed in Scilit:
- Liposomal Hamycin: Reduced Toxicity and Improved Antifungal Efficacy In Vitro and In VivoThe Journal of Infectious Diseases, 1991
- Activity of free and liposome encapsulated streptomycin against Mycobacterium avium complex (MAC) inside peritoneal macrophagesJournal of Antimicrobial Chemotherapy, 1991
- In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patientsJournal of Antimicrobial Chemotherapy, 1990
- Pyrido[3,4-e]-1,2,4-triazines and related heterocycles as potential antifungal agentsJournal of Medicinal Chemistry, 1989
- Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complexJournal of Antimicrobial Chemotherapy, 1989
- Clofazimine and other rimino-compounds: Minimal inhibitory and minimal bactericidal concentrations at different pHs for mycobacterium avium complexTubercle, 1988
- Intracellular Killing of Mycobacterium avium Complex by Rifapentine and Liposome-Encapsulated AmikacinThe Journal of Infectious Diseases, 1987
- In vitro Evaluation of Difloxacin (A-56619), A-56620, and Other 4-Quinolones against Isolates from Cancer PatientsChemotherapy, 1987
- Mycobacterial Infections in. AIDS Patients, with an Emphasis on the Mycobacterium avium ComplexClinical Infectious Diseases, 1986
- Treatment and Prophylaxis of Disseminated Infection Due to Candida albicans in Mice with Liposome-Encapsulated Amphotericin BThe Journal of Infectious Diseases, 1983